Argos Therapeutics Inc fka ARGSQ

[TRACING]

BUY THIS, DO IT...
I have reviewed all available public info, this is a GREAT BUY.

The science is to cause an immune response, they did, in the cancer and hiv studies.

Stock crashed due to STUPID MATH executed without all data being available.

"We are extremely disappointed with these results, which included seventy-five percent of the targeted events needed to permit the primary analysis and assessment of overall survival in the study," said Jeff Abbey , president and chief executive officer of Argos Therapeutics .


....which included seventy-five percent of the targeted events needed to permit the primary analysis.....

translation, the interim data was compiled and reported TOO SOON as TOO MANY PEOPLE WERE STILL ALIVE
THATS A GOOD THING, almost seems like someone executed the interim data report to purposely try to scuttle this study...



this INACCURATE report which crashed this stock is further proven by later data mining by args

A total of 462 patients were enrolled in the ADAPT study and randomized 2:1 between combination treatment with Rocapuldencel-T and sunitinib (combination arm) vs. sunitinib monotherapy (control arm).

The primary efficacy endpoint for the study is a statistically significant improvement in overall survival

The trial was opened in January 2013 and completed enrollment in July 2015 at 107 sites across North America , Europe and Israel .

The most recent interim analysis was conducted by the Independent Data Monitoring Committee (IDMC) in February 2017 (data cut-off as of February 3, 2017 ) after 75% of the targeted number of 290 events (deaths) for the analysis of the primary endpoint of overall survival had occurred.

the estimated median overall survival for the combination arm was 27.7 months (95% Confidence Interval (CI): 23.0, 35.9) compared to 32.4 months (95% CI: 22.5, -) for the control arm.

SO THERE YOU GO, PEOPLE ON ARGS DRUG DIED SOONER 27.7 months THAN THE STANDARD OF CARE 32.4 months, AND THE STOCK CRASHED

BUT WAIT.... LOOKS LIKE THAT WAS WRONG
math, its tough

As a result, the IDMC recommended that the study be discontinued for futility.

fortunately, args said no, and kept the study going and met with the fda after THEY went over the data....

Here is the CORRECTED math as presented to the fda by args in may 2017, this and other NEWER DATA is soon to be presented in spain in september 2017 at ESMO 2017 to the science community via BOTH poster and orals.

Of note, at the time of the IDMC’s February interim analysis, the median duration of follow-up was 20.0 months and more than half the patients in both treatment groups were still alive.
Subsequent to the IDMC meeting, to explore the hypothesis that longer follow-up time may provide useful information to identify a potential beneficial effect of Rocapuldencel-T, the Company conducted a post-hoc subgroup analysis of overall survival in the first third of patients enrolled in the study (n=154). In these patients, for whom generally the longest follow-up data was available, the estimated median overall survival for the combination arm was 30.1 months (95% CI: 23.3, -) compared to 22.2 months (95% CI: 17.2, -) for the control arm. The hazard ratio in this post-hoc subgroup analysis was 0.88 (95% CI: 0.56, 1.36).

OH MY

...a post-hoc subgroup analysis of overall survival in the first third of patients enrolled in the study (n=154)....

....the estimated median overall survival for the combination arm was 30.1 months (95% CI: 23.3, -) compared to 22.2 months (95% CI: 17.2, -) for the control arm. ...

MY OH MY, A COMPLETE REVERSAL OF WHAT THE FIRST REPORT THAT CRASHED THE STOCK INDICATED.

In the erroneous report that crashed the stock, it stated that the ARGS drug would kill you 4.7 months sooner than the STANDARD OF CARE for the disease.

Yet, in the second report where care was taken to COMPARE APPLES AND APPLES they found the ARGS DRUG EXTENDED YOUR LIFE 7.9 MONTHS.

THATS A HUGE DISCREPANCY.

This stock is trading at under 20 pennies and is poised to explode as this information is more fully disclosed and disseminated and a concurrence is provided by the science community, such as from ESMO 2017 3 weeks from now.

Feb 2017 stock crashed from 5 bucks to dollar and a half based on bad math skillz.

May 2017 FDA agrees to decision to continue trial after data is re presented showing ARGS extended life.

Stock continues to fall and is under 20 pennies today.

It is a no brainer. NOT GOING TO GET IN CHEAPER THAN 20 PENNIES LOL, once others get in on this its going up..fast.

Estimated Enrollment: 450
Study Start Date: November 2012
Estimated Study Completion Date: April 2018
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)

The main study
https://clinicaltrials.gov/ct2/show/NCT01582672?term=argos&draw=4&rank=13

A RELATED STUDY
https://clinicaltrials.gov/ct2/show/NCT01482949?term=argos&draw=5&rank=7

ALSO, ARGS GETS FUNDING FROM AIDS FROM THE FED, RECENTLY POSTED SUCCESS WITH THAT AS WELL

July 26 2017
Argos Therapeutics Shares Rally 48.5% as AGS-004 HIV Program Meets Primary Endpoint

09:50 AM EDT, 07/26/2017 (MT Newswires) -- Argos Therapeutics (ARGS) shares were 48.5% higher Wednesday morning after the company reported results from a study of AGS-004 dendritic cell therapy in patients treated during acute HIV infection which met its primary endpoint.
Results showed all six patients demonstrated positive immune response.
"We are encouraged by the results of this study, in which AGS-004 generated a targeted immune response against the HIV virus," said Argos chief scientific officer Charles Nicolette.
"This is an important first step in our goal of not only combating active HIV infection, but also of eliminating the HIV viral reservoir, which has not yet been achieved with any currently available agent or combination therapy. We are hopeful that our strategy of stimulating cells that are latently infected with the HIV virus with the latency-reversing agent vorinostat will enable AGS-004-stimulated memory / effector T-cells to identify and eliminate these latently infected cells, thus potentially eliminating the HIV viral reservoir."